Pharmaceutical compositions comprising teixobactin

1 . A method for treating a bacterial infection in a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition, wherein said pharmaceutical composition is an aqueous solution comprising teixobactin (TXB) and a pegylated phospholipid (PPL);

wherein the PPL solubilizes TXB in the aqueous solution; and

wherein the PPL is a compound of Formula (I):

wherein

R 1 and R 2 are independently an alkyl chain comprising from 4 to 50 carbon atoms, from 0 to 10 double bonds or from 0 to 10 triple bonds;

wherein the alkyl chain is unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, —NO 2 , —COH, —OR′, —COR′, —OCOR′, —COOR′, —CONR′ and —SO 4 , wherein R′ is hydrogen or a C1-C6 alkyl;

n is an integer from 5 to 1000; and

X is a hydrogen, a monovalent cation or a divalent cation; and

wherein the bacterial infection is caused by a Gram-positive bacterium.

2 . The method of claim 1 , wherein R 1 and R 2 are different.

3 . The method of claim 1 , wherein R 1 and R 2 are the same.

4 . The method of claim 1 , wherein R 1 and/or R 2 each comprises from 10 to 20 carbon atoms.

5 . The method composition of claim 1 , wherein R 1 and/or R 2 each comprises no double or triple bonds or wherein R 1 and/or R 2 each comprises at least one double bond.

6 . The method of claim 1 , wherein n is an integer from 30 to 150.

7 . The method of claim 1 , wherein X is selected from the group consisting of hydrogen, Na + , K + ,

NH

4

+

,

Ca 2 + and Mg 2+ .

8 . The method of claim 1 , wherein the PPL is a compound selected from the group consisting of:

1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)],

1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)],

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)], and

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)].

9 . The method of claim 8 , wherein X is NH 4 + .

10 . The method of claim 1 , further comprising a carbohydrate.

11 . The method of claim 10 , wherein the carbohydrate is selected from the group consisting of dextrose, glucose, fructose, galactose, lactose, sucrose, ribose, xylose, threose, mannose and mannitol.

12 . The method of claim 1 , wherein the weight ratio of PPL to teixobactin is about 1:1 (w/w) or greater.

13 . The method of claim 1 , wherein the pharmaceutical composition is administered intravenously.

14 . The method of claim 1 , wherein the Gram-positive bacterium belongs to a genus selected from the group consisting of Staphylococcus, Streptococcus, Bacillus, Clostridium, Propionibacterium, Enterococcus , and Mycobacterium.

15 . The method of claim 14 , wherein the Gram-positive bacterium is methicillin resistant Staphylococcus aureus (MRSA).

16 . The method of claim 14 , wherein the Gram-positive bacterium is vancomycin resistant enterococci (VRE).

17 . The method of claim 14 , wherein the Gram-positive bacterium is Mycobacterium tuberculosis.

18 . The method of claim 1 , wherein the subject is a human.

19 . The method of claim 1 , wherein the Gram-positive bacterium is selected from the group consisting of: Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium kansaii, Mycobacterium gordonae, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactia, Streptococcus faecalis, Streptococcus bovis, Streptococcus pneumoniae , pathogenic, Bacillus anthracis, Bacillus subtilis, Corynebacterium diphtheriae, Corynebacterium jeikeium, Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Clostridium difficile , and Actinomyces israelli.

20 . The method of claim 19 , wherein the Gram-positive bacterium is Mycobacterium avium.